You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.195.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 09:46, 11 January 2025.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 January 2025
Your current IP address is 44.195.68.6. The blocked range is 44.195.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((multiple issues|
((cleanup|reason=layout|date=April 2019))
((cleanup rewrite|date=April 2019))
))
((Infobox organization
| name                = Center for Infectious Disease Research and Policy
| image               = CIDRAPlogo.png
| alt                 = CIDRAP logo
| abbreviation        = CIDRAP
| formation           = 2001
| purpose             = "to prevent illness and death from infectious diseases through epidemiologic research and the rapid translation of scientific information into real-world practical applications and solutions"
| leader_title        = Director
| leader_name         = [[Michael Osterholm|Michael T. Osterholm]]
| parent_organization = Office of the Vice President for Research (OVPR)
| affiliations        = [[University of Minnesota]]
| location            = [[Minneapolis, Minnesota]], U.S.
| coordinates         = ((coord|44.971979|-93.232962|display=inline, title))
| website             = ((URL|http://www.cidrap.umn.edu))
| Twitter             = https://twitter.com/CIDRAP
))
The '''Center for Infectious Disease Research and Policy''' (CIDRAP) is a center within the [[University of Minnesota]] that focuses on addressing public health preparedness and emerging infectious disease response. It was founded in 2001 by [[Michael Osterholm|Dr. Michael Osterholm]], in order to "prevent illness and death from infectious diseases through epidemiological research and rapid translation of scientific information into real-world practical applications and solutions".<ref name=":0">((cite web|url=http://www.fas.org/programs/bio/resource/biothreatagents.html |title=Biological Threat Agents Information |publisher=Federation of American Scientists |access-date=December 22, 2011))</ref> It is not part of the Center for Disease Control or National Institute of Health.

== History ==
Michael Osterholm founded Center for Infectious Disease Research and Policy (CIDRAP) in 2001.<ref name=":0" />

In 2019, the CIDR (Center for Infectious Disease Research in Seattle) was absorbed by the [[Seattle Children's Research Institute]] but the CIDRAP is not the same organization.<ref name=wsha>((Cite web|url=https://www.wsha.org/articles/seattle-childrens-research-institute-partners-with-center-for-infectious-disease-research/|title=Seattle Children's Research Institute partners with Center for Infectious Disease Research|website=Washington State Hospital Association|language=en|access-date=2020-02-13))</ref><ref name=bjscri>((Cite web|url=https://www.bizjournals.com/seattle/news/2018/07/26/seattle-childrens-center-infectious-disease-resear.html|title=Center for Infectious Disease Research to become part of Seattle Children's Research Institute|last=Garnick|first=Coral|date=July 26, 2018|website=Puget Sound Business Journal|access-date=2020-02-12))</ref>

==Primary activities==

===News publishing===
((more citations needed section|date=May 2014))
CIDRAP's news publishing division writes news stories and maintains information on influenza, bioterrorism, and new hot topics.<ref>((Cite journal| last1= Barber| first1= Nicola|last2=Louisa|first2=Stark|title= Online Resources for Understanding Outbreaks and Infectious Diseases |journal=CBE: Life Sciences Education| volume=14|pages=1–5))</ref>

The CIDRAP news team, through the CIDRAP web site, provides daily news updates on emerging infectious diseases, such as pandemic influenza, bioterrorism, food safety, avian influenza, and emerging topics. Along with news articles, the site provides overviews on various infectious disease topics, as well as lists of recent selected literature for each topic. CIDRAP's daily news service has 20,000 current newsletter subscribers and over 36,000 Twitter followers.

=== Influenza Vaccines Roadmap ===
CIDRAP is leading an international collaborative effort to develop an influenza vaccines R&D roadmap (IVR), aimed at accelerating progress toward universal or broadly protective influenza vaccines, one of the most critical global public-health priorities. The IVR serves as a valuable tool to advance the development of novel vaccines that improve the breadth and durability of protection from influenza infection and severe disease. It encompasses incremental improvements in strain-specific seasonal vaccines, as well as transformational changes in vaccine technology designed to induce broad, durable protection against seasonal and pandemic influenza viruses.

=== Antimicrobial Stewardship Program ===
Antimicrobial resistance is a critical global public health issue, and antimicrobial stewardship strategies are key to curtailing the problem. CIDRAP's Antimicrobial Stewardship Project provides current, accurate, and comprehensive information on the topic and works to build an online community to address leading issues.

=== Novel Coronavirus (COVID-19) Resource Center ===
CIDRAP is tracking and analyzing the rapidly evolving novel coronavirus (COVID-19) pandemic. The CIDRAP COVID-19 Resource Center provides a deep well of information for public health experts, business preparedness leaders, government officials, and the public.

=== Resilient Drug Supply Project ===
The Resilient Drug Supply Project focuses on the supply chains and global disruptions for the most critical drugs for life-saving and life-sustaining treatment. Outcomes of this research will improve the healthcare supply system's ability to maintain a steady and adequate supply of critical medicines and supplies worldwide.

=== CIDRAP Leadership Forum ===
Membership in the CIDRAP Leadership Forum (CLF) connects decisionmakers to intelligence they can trust when they need it most. The CLF is a high-value, highly responsive service offered by CIDRAP  that ensures businesses and organizations have rapid access to critical intelligence on emerging infectious disease threats and public health issues. Members say CLF provides insight and analysis they cannot find easily elsewhere.

CLF members connect with Michael T. Osterholm, an international authority on emerging infectious diseases, and  the comprehensive team of CIDRAP experts through special communications, conference calls, webinars, and special CLF events.

== Past Initiatives ==

=== Ebola Vaccine Team B ===
[[Wellcome Trust]] and CIDRAP launched the [[Ebola vaccine]] Team B initiative in November 2014 to assist international efforts to develop in record time safe and effective vaccines against [[Ebola virus disease]]. The project includes 25 distinguished leaders in public health, medicine, bioethics, pharmaceutical manufacturing, and humanitarian relief. The experts provide a fresh perspective (a Team B analysis) of issues being addressed by international collaborators in the areas of funding, research, development, vaccine efficacy and effectiveness determination, licensure, manufacturing, and vaccination strategy (distribution and administration). To date, Team B has published its findings in the following reports:((citation needed|date=August 2023))
* "Completing the Development of Ebola Vaccines: Current Status, Remaining Challenges, and Recommendations"
* "Plotting the Course of Ebola Vaccines: Challenges and Unanswered Questions"
* "Recommendations for Accelerating Development of Ebola Vaccines: Report and Analysis"
* "Fast-Track Development of Ebola Vaccines: Principles and Target Product Criteria"

===BioWatch===
CIDRAP has served as a partner in the federal [[BioWatch]] air-monitoring program. This program is responsible for the constant monitoring for potential [[bioterrorism]]-related agents in cities throughout the United States.<ref>((cite web|url=http://www.cidrap.umn.edu/cidrap/content/bt/bioprep/news/biowatch.html |title= BioWatch program aims for nationwide detection of airborne pathogens |publisher= Center for Infectious Disease Research & Policy |date= February 26, 2003 |access-date= December 22, 2011))</ref> Through its contract with the [[Department of Homeland Security]], CIDRAP provides support for the development of national outdoor and indoor guidance documents, a national epidemiology communications network, and a suite of related program and reference documents.((citation needed|date=August 2023))

===Minnesota Center of Excellence for Influenza Research and Surveillance (MCEIRS)===
The Minnesota Center of Excellence for Influenza Research and Surveillance (MCEIRS), established by the [[National Institutes of Health]] (NIH) and CIDRAP in April 2007, was one of six NIH-supported centers<ref>((cite web| url= http://www.niaid.nih.gov/LabsAndResources/resources/ceirs/Pages/centers.aspx |title=Centers of Excellence for Influenza Research and Surveillance (CEIRS) |publisher= National Institute of Allergy and Infectious Diseases |access-date= December 22, 2011))</ref> in the United States. The activities of the center, including research and surveillance both domestically and abroad, were focused on the detection, epidemiology, and transmission of [[avian influenza]] (AI) viruses with pandemic potential. The primary goal of MCEIRS was to enhance the understanding of how AI viruses evolve, adapt, and spread among animal and human populations,<ref>((cite web |url=http://www.mceirs.umn.edu/mceirs/index.html |title=Minnesota Center of Excellence for Influenza Research & Surveillance |publisher=Center for Infectious Disease Research & Policy |access-date=December 22, 2011 |url-status=dead |archive-url= https://web.archive.org/web/20120324065203/http://www.mceirs.umn.edu/mceirs/index.html |archive-date=March 24, 2012 ))</ref> the center closed in April 2014.

===Influenza training===
The Center of Excellence for Influenza Research and Surveillance has developed an online training portal that provides e-learning modules on topics related to avian influenza and influenza in general.((citation needed|date=August 2023))

===CIDRAP Comprehensive Influenza Vaccine Initiative (CCIVI)===
In December 2009 a grant by the [[Alfred P. Sloan Foundation]] started the CIDRAP Comprehensive Influenza Vaccine Initiative. The primary goal of CCIVI was to review all aspects of 2009-2010 H1N1 influenza vaccine preparedness and response and to review the scientific and programmatic basis for the current seasonal influenza vaccine efforts. The final report, published October 15, 2012, is a review of more than 12,000 peer-reviewed publications, documents, transcripts and notes dating back to 1936 and interviews and follow up with 88 experts in influenza vaccine research, development, and use.<ref>((cite web| last= Center for Infectious Disease Research and Policy| title= The Compelling Need for Game-Changing Influenza Vaccines: An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future| url= http://www.cidrap.umn.edu/cidrap/center/mission/articles/ccivi-landing.html| website= cidrap.umn.edu| publisher= CIDRAP| access-date= 15 October 2012| archive-date= 6 May 2013| archive-url= https://web.archive.org/web/20130506161233/http://www.cidrap.umn.edu/cidrap/center/mission/articles/ccivi-landing.html| url-status= dead))</ref>

===Public Health Practices (PHP)===
((more citations needed section|date=May 2014))
Public Health Practices (PHP) was a curated compendium of tools, strategies, and downloadables created by US health agencies and partners to prepare for and respond to the health consequences of disasters and emergencies. The project was ended in December 2014.

Practitioners can still search the one-stop shop of real-world resources by hazard, strategy, partners, geography, groups being served, agency, tool, language, and key word. PHP encourages peer-to-peer exchange of practices by accepting submissions to the site, showcasing examples in theme-based email newsletters, and hosting social media channels for practitioners.

Public Health Practices features:
* More than 400 practices addressing a wide range of hazards
* Successful coalitions and details about what made them possible
* Stories on how projects were created
* Communication materials in 40 languages to download or adapt
* A search tool that allows users to apply filters to narrow results as needed
* A simple submissions process to encourage practitioners to share their work
* Peer-to-peer information exchange via social media

==Notes==
((Reflist))

==External links==
* ((Official website|http://www.cidrap.umn.edu/))
** [http://www.cidrap.umn.edu/compelling-need-game-changing-influenza-vaccines Comprehensive Influenza Vaccine Initiative (CCIVI)]
** [http://www.cidrap.umn.edu/public-health-practices Public Health Practices]
* [http://www.mceirs.umn.edu/ Minnesota Center of Excellence for Influenza Research & Surveillance (MCEIRS)] ((Webarchive|url=https://web.archive.org/web/20130629213221/http://www.mceirs.umn.edu/ |date=2013-06-29 ))

((University of Minnesota campus))
((Authority control))

[[Category:Public health organizations]]
[[Category:University of Minnesota]]

Pages transcluded onto the current version of this page (help):

Center for Infectious Disease Research and Policy (edit)
Template:Ambox (view source) (template editor protected)
Template:Authority control (view source) (template editor protected)
Template:Box-shadow border (view source) (template editor protected)
Template:Category handler (view source) (protected)
Template:Citation needed (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Cite web (view source) (protected)
Template:Cleanup (view source) (template editor protected)
Template:Cleanup rewrite (view source) (template editor protected)
Template:Colored link (view source) (template editor protected)
Template:Comma separated entries (view source) (template editor protected)
Template:Coord (view source) (protected)
Template:DMC (view source) (template editor protected)
Template:DMCA (view source) (template editor protected)
Template:Dated maintenance category (view source) (template editor protected)
Template:Dated maintenance category (articles) (view source) (template editor protected)
Template:Delink (view source) (protected)
Template:FULLROOTPAGENAME (view source) (template editor protected)
Template:Fix (view source) (protected)
Template:Fix/category (view source) (protected)
Template:Hlist/styles.css (view source) (protected)
Template:Icon (view source) (template editor protected)
Template:If empty (view source) (protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox organization (view source) (template editor protected)
Template:Longitem (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:More citations needed section (view source) (template editor protected)
Template:Multiple issues (view source) (template editor protected)
Template:Multiple issues/styles.css (view source) (template editor protected)
Template:Navbox (view source) (template editor protected)
Template:Ns has subpages (view source) (protected)
Template:Official website (view source) (template editor protected)
Template:Plainlist/styles.css (view source) (protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SUBJECTSPACE formatted (view source) (template editor protected)
Template:Sp (view source) (template editor protected)
Template:Template other (view source) (protected)
Template:Terminate sentence (view source) (template editor protected)
Template:URL (view source) (template editor protected)
Template:Unbulleted list (view source) (template editor protected)
Template:University of Minnesota campus (edit)
Template:Webarchive (view source) (template editor protected)
Template:White (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Coordinates (view source) (protected)
Module:Coordinates/styles.css (view source) (protected)
Module:Delink (view source) (protected)
Module:EditAtWikidata (view source) (protected)
Module:Icon (view source) (template editor protected)
Module:Icon/data (view source) (template editor protected)
Module:If empty (view source) (protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:List (view source) (protected)
Module:Math (view source) (protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Ns has subpages (view source) (protected)
Module:Official website (view source) (template editor protected)
Module:Separated entries (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:Text (view source) (template editor protected)
Module:URL (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Webarchive (view source) (template editor protected)
Module:Webarchive/data (view source) (template editor protected)
Module:Yesno (view source) (protected)

Return to Center for Infectious Disease Research and Policy.

Retrieved from "https://en.wikipedia.org/wiki/Center_for_Infectious_Disease_Research_and_Policy"